TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for TG Therapeutics in a research report issued to clients and investors on Tuesday, July 11th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings per share of $0.01 […]
StockNews.com lowered shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a sell rating in a report issued on Tuesday morning. Several other research analysts also recently commented on TGTX. Cantor Fitzgerald restated an overweight rating and set a $24.00 price objective on shares of TG Therapeutics in a report on […]
StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a sell rating to a hold rating in a report released on Monday morning. A number of other brokerages also recently commented on TGTX. Cantor Fitzgerald reaffirmed an overweight rating and issued a $24.00 price target on shares of TG Therapeutics in a report […]
TG Therapeutics, Inc. (NASDAQ:TGTX – Get Rating) Director Sagar Lonial sold 34,854 shares of TG Therapeutics stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $23.37, for a total value of $814,537.98. Following the sale, the director now owns 93,878 shares of the company’s stock, valued at […]